A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples